Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs Heron Therapeutics Inc (HRTX) Price & Performance

Blackrock IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs Heron Therapeutics Inc — how do they compare? Blackrock Inc trades at $1,148.83 (market cap $175.22B), while Heron Therapeutics Inc trades at $0.33 (market cap $63.41M). The key difference: Blackrock Inc is far larger — about 2763.3× Heron Therapeutics Inc's market cap, and Blackrock Inc pays a 2.03% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

BLKHRTX
Market Cap
$175.22B$63.41M
Volume
641,547
Sector
FinancialsHealth
52-Week High
$1.20K$1.49
52-Week Low
$922.90$0.32
Enterprise Value
$176.32B$161.31M
Dividend Yield
2.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

BlackRock (BLK) trades at $1,136.39, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $20.4B in 2024 to $24.2B in 2025, though net income margin compressed to 22.93%. Recent earnings beats and a 78.79% analyst buy rating support positive sentiment, while the stock trades near resistance at $1,144.

BLK presents a compelling investment case with consistent earnings outperformance and strong institutional support, though investors face risks from margin compression and legal scrutiny. The consensus price target of $1,350 suggests 18.8% upside potential, balanced by overbought technical indicators and competitive pressures in asset management.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX